RESUMO
BACKGROUND: Interactions between cells and the basement membrane glycoprotein laminin are altered during colon cancer progression. Colon carcinoma and normal mucosa cells express a variety of laminin-binding proteins, including the 67-kd laminin receptor (67 LR) and a 31-kd human laminin-binding protein (HLBP31) homologous to the 31-kd human IgE-binding protein/galactoside-binding lectin. PURPOSE: To investigate whether various laminin-binding proteins are differentially expressed in human colon carcinoma, we studied messenger RNA (mRNA) levels of the 67 LR and HLBP31 in matched tumor and adjacent normal mucosa samples from a series of 21 patients. METHODS: Total cellular RNA from tumor and normal mucosa was isolated and analyzed by Northern and slot blot hybridization. In addition, HLBP31 protein levels were assessed by the immunoblot technique. Quantitative laminin affinity chromatography was also used to measure the synthesis of HLBP31 protein in five human cancer cell lines. RESULTS: The steady-state mRNA level of HLBP31 was downregulated (i.e., decreased) in 18 of 21 human colon carcinomas compared with the level in their corresponding normal colonic mucosa. On average, the level of HLBP31 mRNA was decreased 50% +/- 30% (+/- SD) in the colon cancers. The mean ratio of colon cancer HLBP31 mRNA to adjacent normal mucosa HLBP31 mRNA was twofold lower in primary tumors of patients with metastases (0.3 +/- 0.2 SD) than in primary tumors of patients free of metastatic lesions (0.6 +/- 0.2 SD). The differences between the two groups of patients were statistically significant (P less than .05, Wilcoxon-Mann-Whitney test). We have previously shown that the ratio of colon cancer 67 LR mRNA to corresponding normal mucosa 67 LR mRNA was increased in the same patient population. When the two ratios (ratio of cancer to normal HLBP31 mRNA and ratio of cancer to normal 67 LR mRNA) were compared, HLBP31 mRNA/67 LR mRNA was significantly lower (P less than .05) in primary tumors with metastases (mean +/- SD, 0.3 +/- 0.2) than in primary cancers without metastases (mean +/- SD, 0.7 +/- 0.5). The steady-state level of HLBP31 mRNA was directly correlated with the amount of HLBP31 protein in both colon tissue samples and human cancer cell lines. CONCLUSION: HLBP31 mRNA expression in colon cancer tissues is modulated inversely to that of 67 LR mRNA expression. The down-regulation of HLBP31 appears to be associated with the metastatic capabilities of colon cancer cells. IMPLICATIONS: Prospective studies on a large cohort should determine if the systematic detection of HLBP31 and 67 LR protein and/or mRNA can be a valuable adjunct in the prognostic evaluation of primary colon cancers.
Assuntos
Carcinoma/química , Neoplasias do Colo/química , Laminina/metabolismo , RNA Mensageiro/análise , Receptores Imunológicos/genética , Sequência de Aminoácidos , Sequência de Bases , Colo/química , DNA/isolamento & purificação , Humanos , Dados de Sequência Molecular , Metástase Neoplásica , Receptores Imunológicos/análise , Receptores de Laminina , Células Tumorais CultivadasRESUMO
Women's attitude concerning menstruations is changing towards achieving extended cycles with few or even suppressed menses, in view of the unpleasant perimenstrual bleeding, pain and discomfort pattern that may accompany menstruation. Use of combined oral estrogen-progestin contraception in extended "cycles" of 3, 6 and 12 or more months is now under active study. Extended cycle contraception is abided by a better compliance than conventional cycle contraception with ensuing optimized contraceptive effectiveness. Hypothetically, transdermal or transvaginal combined contraception could be used in extended cycles. Tolerance is comparable for both methods and unpredicted bleeding, initially more frequent during long cycle treatment tends to become less frequent after about 6 months a compared with conventional cycles. Usual safety parameters appear to be similar under both contraceptive modalities. Comfort and well being brought by extended cycle use (5 to 10 times fewer days of bloating or perimenstrual pain) allow to estimate that, according to acceptability studies, 10 to 40 percent of women of reproductive age would currently choose extended cycle contraception.
Assuntos
Anticoncepcionais Orais Combinados/uso terapêutico , Administração Cutânea , Adulto , Amenorreia , Atitude Frente a Saúde , Anticoncepcionais Orais Combinados/administração & dosagem , Anticoncepcionais Orais Combinados/efeitos adversos , Preparações de Ação Retardada , Estrogênios , Feminino , Humanos , Menstruação , Cooperação do Paciente , ProgestinasRESUMO
The infection by Chlamydia trachomatis is a serious infection that affects the male and female tractus, and that induces complications such as infertility and extrauterine pregnancy. The antibiotic treatment needed must necessarily reach the intracellular milieu to be efficient enough to eradicate the infection.
Assuntos
Infecções por Chlamydia/diagnóstico , Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis , Doenças Urogenitais Femininas/diagnóstico , Doenças Urogenitais Femininas/tratamento farmacológico , Doenças Urogenitais Masculinas , Feminino , Doenças Urogenitais Femininas/microbiologia , Humanos , MasculinoRESUMO
Adenomyosis is a frequent entity, with difficult diagnosis, often obtained by pathological analysis performed after hysterectomy. This condition can cause abnormal uterine bleeding and dysmenorrhea, frequent reasons for consultation and hysterectomy. The development of ultrasonographic and magnetic resonance imaging techniques allow preoperative diagnosis. They also permit the use of hysteroscopic techniques for conservative uterine surgery, and have brought diagnosis and management of this disease to the front of the scene. This article reviews the pathological description of the disease, its epidemiology, clinical presentations, useful and necessary explorations, etiopathogeny and available therapies.
Assuntos
Endometriose/diagnóstico , Doenças Uterinas/diagnóstico , Diagnóstico Diferencial , Dismenorreia/etiologia , Endometriose/diagnóstico por imagem , Endometriose/patologia , Endometriose/terapia , Feminino , Humanos , Histerectomia , Histeroscopia/métodos , Imageamento por Ressonância Magnética , Menorragia/etiologia , Ultrassonografia , Doenças Uterinas/diagnóstico por imagem , Doenças Uterinas/patologia , Doenças Uterinas/terapiaRESUMO
The first gynecological consultation is particularly important for teens. It not only allows to answer the patient's questions, for instance, by prescribing a contraception, but also to provide an adequate information about some subjects, including sexuality, sexually transmitted diseases, and some life-style habits. This article will review the various important points of this first consultation.
Assuntos
Doenças dos Genitais Femininos/prevenção & controle , Ginecologia , Saúde da Mulher , Adolescente , Feminino , HumanosRESUMO
Contraception of the diabetic patient is an important matter. It allows to plan adequately the pregnancies, should respect carbohydrate metabolism and should consider the risk of diabetic complications. This review article describes the contraceptive techniques for diabetic patients.
Assuntos
Anticoncepção , Diabetes Mellitus , Gravidez em Diabéticas , Adulto , Fatores Etários , Metabolismo dos Carboidratos , Complicações do Diabetes/etiologia , Feminino , Humanos , Gravidez , Fatores de RiscoRESUMO
Prevalence of diabetes mellitus (types 1 and 2) in postmenopausal women is about 10-20% according to age. It can be associated with a metabolic syndrome in about 60% of cases, thereby severely increasing cardiovascular risk (among others) in these women. Estrogen or estrogen-progestin replacement therapy does not usually impair diabetes control. It will be submitted to the same indications/contraindications, in relation with the risk/benefit balance, as for all other postmenopausal women. However, increased risks inherent to diabetic subjects concerning metabolism, coagulation/hemostasis, and cardiovascular disease, should be considered. Therefore, estrogen in minimal effective dosages, eventually by transdermal route, as well as metabolically neutral progestins near to progesterone should be preferred. In case of pre-existing or occurring vascular problems, a careful approach or even suppression of replacement therapy should prevail.
Assuntos
Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 2/complicações , Terapia de Reposição Hormonal/efeitos adversos , Menopausa , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Fatores de RiscoRESUMO
The expression of the 67-kD laminin receptor (67LR) and the 31-kD human laminin-binding protein (HLBP31), two proteins involved in cancer cell laminin interaction, was evaluated on 30 ovarian cancer specimens. Expression of the 67LR was increased (up to 2.5-fold, in 87% of the patients), while HLBP31 expression was downregulated in cancer cells compared with the normal tissue, as detected by northern blotting and immunohistochemistry. The immunohistochemical study demonstrated that the 67LR was significantly overexpressed (P < 0.05) in the group of patients whose cytoreductive surgery was suboptimal, and those with poor clinical outcome. No correlation was observed between HLBP31 expression and clinicopathological features. Increased expression of the 67LR appears to correlate with the invasive phenotype of ovarian cancer cells and suggests a role of the latter in ovarian cancer invasion.
Assuntos
Proteínas de Transporte/análise , Laminina/metabolismo , Neoplasias Ovarianas/química , Receptores de Laminina/análise , Feminino , Humanos , Imuno-Histoquímica , Peso Molecular , Invasividade Neoplásica , Neoplasias Ovarianas/patologiaRESUMO
Previous immunohistochemical data from our laboratory have demonstrated that expression of the 67 kD laminin receptor (67LR), a cancer-associated, high-affinity laminin-binding protein, is upregulated in ovarian carcinoma cells compared with normal serosal cells, and that this increased expression in cancer cells could be related to patient outcome. The aim of this study was to validate MLuC5, a monoclonal antibody that recognises the 67LR, as a tool to perform future immunohistochemical studies on larger populations of ovarian carcinoma patients. Expression of the 67LR was determined in 51 primary human ovarian carcinoma samples using immunohistochemistry and MLuC5. The 67LR was detected in ovarian carcinoma cell clusters of variable extent. Analysis of the data determined that 67LR expression was significantly increased in the samples from patients with disease progression, compared with those with no evidence of disease after completion of primary therapy, and in pooled grade 2 and 3 tumours compared to borderline and grade 1 tumours (P < 0.05, chi-squared test). No other significant correlation between 67LR expression and other clinicopathological parameters could be established. These data suggest that the 67LR is correlated to ovarian tumour progression. Detection of the 67LR using this monoclonal antibody could constitute an interesting parameter in prognosis determination of ovarian cancer.
Assuntos
Adenocarcinoma/metabolismo , Carcinoma/metabolismo , Neoplasias Ovarianas/metabolismo , Receptores de Laminina/metabolismo , Anticorpos Monoclonais , Progressão da Doença , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Ovarianas/patologia , PrognósticoRESUMO
Human placentation is a complex biological phenomenon that results from precisely regulated interactions between cells and the extracellular matrix. Galectin- 1 and galectin-3 belong to a newly defined family of galactose-binding lectins that can bind several glycoconjugates such as the basement membrane glycoprotein laminin, and are involved in many biological events including cell adhesion. In this study, the expression of these two galectins in first and third trimester normal human placenta was examined using single and double immunohistochemical staining and specific antibodies for galectins and cytokeratins. Galectin-3 was detected in all trophoblastic lineages including villous cytotrophoblasts and extravillous trophoblasts (trophoblastic cell columns, infiltrating trophoblasts, endovascular trophoblasts and placental bed giant cells). On the contrary, galectin-1 distribution was restricted to endometrium. A reduction of galectin-3 expression was observed from the villous trophoblasts to the trophoblastic cell columns. This pattern correlated with the switch from a proliferative to a migratory phenotype. Galectin-1 and galectin-3 were both detected in maternal decidual cells. Our data demonstrate a specific pattern of galectin-1 and galectin-3 expression in trophoblastic tissue, and suggest these lectins could contribute to cell-cell and cell matrix interactions of trophoblast during placentation.
Assuntos
Antígenos de Diferenciação/metabolismo , Hemaglutininas/metabolismo , Placenta/metabolismo , Proteínas da Gravidez/metabolismo , Trofoblastos/metabolismo , Diferenciação Celular , Feminino , Galactose , Galectina 1 , Galectina 3 , Humanos , Imuno-Histoquímica , Lectinas , Placenta/citologia , Gravidez , Transdução de Sinais , Trofoblastos/citologiaRESUMO
Galectins are beta-galactoside-binding lectins that play multiple roles during tumor progression. Previous work conducted in our laboratory has demonstrated decreased galectin-3 expression in carcinomas from colon, breast, ovary and endometrium, compared to the corresponding normal tissues. In this study, we examined the pattern of galectin-3 expression by immunohistochemistry in a group of 10 basal cell carcinomas of the skin. In the surrounding normal skin, galectin-3 immunostaining was found predominantly in the middle epidermis (spine layer) and eccrine sweat glands. Compared to the normal epidermal cells, basal carcinoma cells observed in all 10 samples examined presented with significantly decreased galectin-3 immunostaining. These data further demonstrates that galectin-3 is down-regulated in a variety of human cancers, including basal cell carcinoma.
Assuntos
Antígenos de Diferenciação/biossíntese , Carcinoma Basocelular/metabolismo , Regulação Neoplásica da Expressão Gênica , Proteínas de Neoplasias/deficiência , Neoplasias Cutâneas/metabolismo , Antígenos de Diferenciação/genética , Carcinoma Basocelular/genética , Carcinoma Basocelular/patologia , Matriz Extracelular/metabolismo , Galectina 3 , Neoplasias de Cabeça e Pescoço/genética , Neoplasias de Cabeça e Pescoço/metabolismo , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Técnicas Imunoenzimáticas , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/genética , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/patologia , Células Tumorais Cultivadas/metabolismoRESUMO
Alterations of tumor cell interactions with laminin, a basement membrane glycoprotein, are consistent features of the invasive and metastatic phenotype. Qualitative and quantitative changes in the expression of cell surface laminin-binding proteins have been correlated with the ability of cancer cells to cross basement membranes during the metastatic cascade. Such phenotypic modifications are usually associated with poor prognosis. In this study, the authors examined the possibility that expression of three laminin-binding proteins, the 67-kD laminin receptor (67LR), galectin-1, and galectin-3, is altered in human endometrial cancer in a fashion similar to that reported in other carcinomas, such as breast, colon, and ovarian cancer. Twenty advanced uterine adenocarcinomas were analyzed for expression of these three molecules using immunoperoxidase staining and specific antibodies. The authors found a significant increase in the expression of the 67LR and galectin-1 in cancer cells compared with normal adjacent endometrium (P = .0004 and .0022, respectively). As observed in other carcinomas, a significant down-regulation of galectin-3 expression was found in endometrial cancer cells compared with normal mucosa (P = .02). In the galectin-3 positive tumors, galectin-3 was detected in the cytoplasm and/or nucleus of cancer cells. Interestingly, tumors in which galectin-3 was detected only in the cytoplasm were characterized by deeper invasion of the myometrium than lesions where galectin-3 was found both in nucleus and cytoplasm (P = .02). This study shows an alteration of nonintegrin laminin-binding protein expression in advanced human endometrial cancer. Further studies on larger populations should determine the prognostic value of the detection of these laminin-binding proteins in endometrial carcinoma. Inverse modulation of the 67LR and galectin-3 appears to be a phenotypical feature of invasive carcinoma.
Assuntos
Adenocarcinoma/patologia , Antígenos de Diferenciação/biossíntese , Hemaglutininas/biossíntese , Receptores de Laminina/biossíntese , Neoplasias Uterinas/patologia , Adenocarcinoma/metabolismo , Anticorpos Monoclonais/análise , Antígenos de Diferenciação/imunologia , Regulação para Baixo/fisiologia , Feminino , Galectina 1 , Galectina 3 , Hemaglutininas/imunologia , Humanos , Pessoa de Meia-Idade , Invasividade Neoplásica , Receptores de Laminina/imunologia , Estudos Retrospectivos , Neoplasias Uterinas/metabolismoRESUMO
In postmenopausal women, partly in relation to advancing age and partly due to oestrogen deficiency, there is a frequent increase in body weight, and more specifically, in android fat distribution. In addition, loss of ovarian function is associated with the development of a more atherogenic profile with increased triglycerides, LDL-cholesterol and its smaller dense subfractions, decreased HDL- and HDL2-cholesterol and, potentially, an irregular increase in Lp(a). Not only does oestrogen therapy counteract all these changes towards a definitely less atherogenic profile but oestrogens seem also implicated in reducing LDL oxidative products, in favouring a higher ratio of prostacyclin to thromboxane and, potentially, of endothelium derived relaxing factor to endothelin, and also in acting as a calcium antagonist in the vessel wall. All of these favourable vascular effects are not solely attributable to lipid-related oestrogen effects. Excess weight and central obesity, diet changes and lack of exercise, more frequent with advancing age, all concur to alter glucose tolerance and increase insulin resistance during the postmenopause. Impaired glucose tolerance and diabetes mellitus may be found in nearly 20% of women aged 55 to 65 years. In addition, oestrogen deficiency may be further responsible for decreased pancreatic insulin secretion and alteration of its metabolic clearance rate-changes that can be reversed toward improved insulin secretion and sensitivity by oestrogen treatment in small dosages. By contrast, synthetic androgenic progestins can counteract these effects of oestrogens more than progesterone derivatives do, and they may partly help to promote insulin resistance and hyperinsulinism.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Glucose/metabolismo , Metabolismo dos Lipídeos , Pós-Menopausa/metabolismo , Arteriosclerose/fisiopatologia , Estrogênios/fisiologia , Feminino , HumanosRESUMO
To test an immunological hypothesis proposed to explain the pathogenesis of cerebrovascular thrombosis in steroid users, circulating immune complexes were assayed in the sera from 6 control subjects, 14 ever users of oral contraceptive having developed a neurological ischaemic accident, and 7 patients with the same clinical history during use of other sex steroid not containing ethinylestradiol. Beaumont's ammonium sulfate and polyethylene glycol precipitation methods, together with a specific method of isolation of circulating immune complexes using affinity chromatography on Protein A, were used. Radioactivity from labeled ethinylestradiol added to the sera before precipitation was monitored in the precipitates to detect anti-ethinylestradiol antibodies. There were no significant differences for these parameters in the three groups. However, protein content and 3H-EE activity in the precipitates were equally and dramatically reduced after affinity chromatography in the three groups. These latter results do not support the presence of antibodies against ethinylestradiol in steroid users with cerebrovascular thrombosis. Moreover, our data suggest a lack of specificity of Beaumont's method for the isolation of immune complexes containing anti-ethinylestradiol antibodies.
Assuntos
Complexo Antígeno-Anticorpo/sangue , Esteroides/imunologia , Trombose/imunologia , Adulto , Sulfato de Amônio , Precipitação Química , Anticoncepcionais Orais Hormonais/imunologia , Etinilestradiol/imunologia , Feminino , Humanos , Embolia e Trombose Intracraniana/imunologia , Masculino , PolietilenoglicóisRESUMO
Previous reports speculated that vascular events could be related to the development of antibodies against synthetic steroids contained in oral contraceptives or other hormonal treatments. This study describes original immunoassays designed to detect antisynthetic steroid antibodies. In a first step, the assays were characterized and validated using animal-raised antisteroid antibodies. In a second step, a population of 88 oral contraceptive users, 47 of them having developed a vascular thrombosis during synthetic steroid use and 41 serving as healthy control users, were tested. Detection of antibodies against ethinylestradiol, levonorgestrel, norethisterone, cyproterone acetate, and gestodene showed that the values obtained in normal oral contraceptive users as well as thrombosis patients are very low, and show no statistically significant difference between the two groups tested. Taken together, these data indicate that the "immunological hypothesis" related to antisteroid antibodies is unlikely to explain the pathogenesis of vascular events in oral contraceptive users.
Assuntos
Anticorpos/análise , Anticoncepcionais Orais/efeitos adversos , Anticoncepcionais Orais/imunologia , Tromboflebite/etiologia , Adolescente , Adulto , Antagonistas de Androgênios/efeitos adversos , Antagonistas de Androgênios/imunologia , Anticorpos/imunologia , Anticoncepcionais Orais Sintéticos/efeitos adversos , Anticoncepcionais Orais Sintéticos/imunologia , Acetato de Ciproterona/efeitos adversos , Acetato de Ciproterona/imunologia , Etinilestradiol/efeitos adversos , Etinilestradiol/imunologia , Feminino , Humanos , Técnicas Imunoenzimáticas , Levanogestrel/efeitos adversos , Levanogestrel/imunologia , Pessoa de Meia-Idade , Noretindrona/imunologia , Norpregnenos/efeitos adversos , Norpregnenos/imunologia , Congêneres da Progesterona/efeitos adversos , Congêneres da Progesterona/imunologiaRESUMO
Galectin-3 is a laminin binding protein which expression is altered in a variety of human carcinomas including colon, breast and endometrium. In these tumors, we consistently observed a down regulation of galectin-3 expression related to increased aggressiveness. Galectin-3 belongs to a family of galactose-binding lectins and binds laminin through its numerous poly-N-acetyllactosamine chains. To date, the exact role of galectin-3 in the complex interactions between cancer cells and laminin has not been clearly defined. Adhesion of melanoma cells to laminin is a critical event during tumor invasion and metastasis. In this study, we explore the possibility that galectin-3 could modulate attachment of two human melanoma cell lines to laminin. A2058 and A375 melanoma cell expressed galectin-3 on their surface as demonstrated by immunofluorescence, and attached to laminin in an in vitro assay. We demonstrate that neither recombinant galectin-3 nor an affinity purified antigalectin-3 antiserum altered adhesion of A2058 or A375 melanoma cells to laminin. Our data strongly suggest that galectin-3 is not a key element in adhesion of the melanoma cells to laminin. These results are not surprising in light of the observation that galectin-3 expression is down regulated in cancer and that increased adhesion to laminin is a constant feature of invasive cancer cells.
Assuntos
Antígenos de Diferenciação/fisiologia , Laminina/fisiologia , Lectinas/fisiologia , Melanoma/patologia , Antígenos de Diferenciação/análise , Adesão Celular/efeitos dos fármacos , Galectina 3 , Humanos , Invasividade Neoplásica , Proteínas Recombinantes/farmacologia , Células Tumorais CultivadasRESUMO
Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system. These preparations appear to be particularly interesting as they provide additional possibilities for individualizing contraceptive therapy.
Assuntos
Anticoncepcionais Femininos , Desogestrel , Anticoncepcionais Orais Combinados , Implantes de Medicamento , Etinilestradiol/administração & dosagem , Feminino , Humanos , Dispositivos Intrauterinos , Levanogestrel/administração & dosagem , Norpregnenos/administração & dosagem , Compostos de Vinila/administração & dosagemRESUMO
Ovarian carcinomas constitute the major cause of the mortality and morbidity in gynaecology. Most ovary carcinomas are epithelial tumours. Our understanding of ovarian cancerogenesis has been hampered by the lack of a well defined precursor lesion, the lack of knowledge about tumour progression, and by the relative inaccessibility of the ovaries in the abdominal cavity. Recent studies using experimental models allow us to better define the fundamental mechanisms of carcinogenesis from the serous ovarian cells and of invasion of the abdominopelvic cavity by proximity. This review article tries to update on epidemiology, genetic syndromes, biology, screening, and therapy of these epithelial tumours, and about the new directions taken by basic and clinical research. We will present data concerning oncogenes and tumour suppressor genes involved in epithelial ovarian tumours, regulation of tumour cells by growth factors, genes involved in tumour invasion, and mechanisms used by the cancer cell to resist to therapies. Non-epithelial ovarian tumours will not be examined in this manuscript.
Assuntos
Carcinoma , Neoplasias Ovarianas , Biomarcadores Tumorais , Carcinoma/diagnóstico , Carcinoma/epidemiologia , Carcinoma/genética , Carcinoma/terapia , Feminino , Genes Supressores de Tumor/genética , Humanos , Oncogenes/genética , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/epidemiologia , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/terapia , Fatores de RiscoRESUMO
It has been demonstrated that postmenopausal hypoestrogenia induces numerous complications including osteoporosis and increased risk of cardiovascular disease. Oral or transdermal administration of estrogens can reduce these risks, but induces adverse effects. Recently, raloxifene, a new molecule from the benzothiophene family, has been demonstrated to prevent postmenopausal bone loss. It does not induce endometrial stimulation, and recent studies show that it could reduce breast cancer incidence. Its mode of action, consisting of mixed agonist and antagonistic estrogenic actions on different organs and systems, allows to classify it into the selective estrogen receptor modulator (SERM) family. In this review article, we will describe the characteristics of the molecule, its mode of action and the potential indications of its clinical use.
Assuntos
Cloridrato de Raloxifeno/farmacologia , Receptores de Estrogênio/efeitos dos fármacos , Moduladores Seletivos de Receptor Estrogênico/farmacologia , Neoplasias da Mama/prevenção & controle , Antagonistas de Estrogênios/farmacologia , Antagonistas de Estrogênios/uso terapêutico , Feminino , Humanos , Osteoporose Pós-Menopausa/prevenção & controle , Cloridrato de Raloxifeno/efeitos adversos , Cloridrato de Raloxifeno/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/uso terapêuticoRESUMO
AIM OF THE STUDY: To evaluate the efficacy of transvaginal sonography and saline infusion hysterosonography, as imaging tools, for the diagnosis of uterine abnormalities. METHODS: Two hundred seventy five patients were examined using transvaginal sonography (TVS) and saline infusion sonography (SIS), and the results were compared. RESULTS: Saline infusion sonography was performed in 88.4% of the cases. The most frequent cause of SIS failure was the presence of a stenotic cervix. In case of normal TVS, SIS allowed to visualize a polypoid lesion that was not demonstrated by TVS in 20.4% of the cases (n = 29/142). Saline infusion sonography confirmed the diagnosis of focal lesion suspected after TVS in all cases (n = 36). Finally, the localization of intramyometrial or submucous myomas was improved by SIS: myomas diagnosed by TVS as intramyometrial were demonstrated by SIS to be submucous in 41% of the cases (n = 23/56). CONCLUSIONS: Our results confirm that saline infusion sonography is a useful complementary tool for transvaginal sonography in the diagnosis of focal endometrial lesions and for the localization of fibromyomas.